Prevention and Treatment of Type 1 Diabetes with Insulin Analog Molecules
Diamune specializes in the development and production of innovative IgG Fc-Fusion insulin analogs. Meticulously engineered to mitigate and prevent autoimmune diabetes via immune modulation, Diamune also houses a “once-a-week” Ultra Long-Acting Insulin to elevate standards of diabetes management.
Diamune Pipeline
AKS-107 is an Fc-insulin fusion protein designed to interrupt the process leading to insulin autoimmunity. Diamune Therapeutics, Inc. has licensed this patent from Akston Biosciences Corporation to continue the development that was begun with a partnership with the Helmsley Charitable Trust and the National Institutes of Health (NIH) in the early development stages.
AKS-440 is a novel human insulin candidate based on an Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. Diamune Therapeutics, Inc. has licensed this patent from Akston Biosciences Corporation to continue the development of this therapy. It is currently in pre-clinical development.